Sepracor Inc. http://www.alacrastore.com/company-snapshot/Sepracor_Inc-1053164 Monday, October 06, 2008 7:04:05 PM 1053164 Sepracor Inc. en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/newstex/PRN-0005-27074533newstex/PRN-0005-27074533xml MONTVALE, N.J., Jul. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today confirmed that its subsidiaries, Barr Laboratories, Inc. and PLIVA-Hrvatska D.O.O., have initiated a challenge...0400000004002000040020060401600004016031070000000701400007014012070030000700300102000000020020000200200802002006020020041300000013010000130100057/31/2008 12:23:41 PM1800000018020000180180001900000019001000PR Newswire USPRN-0005-27074533BARR PHARMACEUTICALS INCSEPRACOR INCBRLSEPRNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1910632ccbn/T1910632norm...Ladies and gentlemen, welcome to Sepracor's second quarter #### earnings conference call. Hosting the call for Sepracor is Mr. Adrian Adams, President and Chief Executive Officer. At this time, all participants have been placed in a listen-only mode, and the floor will be open for your questions following the presentation. (OPERATOR INSTRUCTIONS). It is now our pleasure to turn the call over to our host, Mr. Adrian Adams. Sir, you may begin. ... 7/29/2008 10:48:00 AMSepracor54.0000FinalSepracor Q2 2008 Earnings Conference Call TranscriptSEPR8:30am ETTranscriptT1910632Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/BW-0001-26922918newstex/BW-0001-26922918xml Jul. ##, #### (Business Wire) -- Sepracor Inc. (Nasdaq: SEPR) will announce its second quarter #### financial results on July ##, ####. In conjunction with the press release, Sepracor will host a conference call and live webcast beginning...0400000004016000040160480401601804002000040020060700000007014000070140127/25/2008 7:17:13 AM180000001800400018008000Business WireBW-0001-26922918ICON PLCSEPRACOR INCICLRSEPRNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26893012newstex/PRN-0005-26893012xml ROCKVILLE, Md., Jul. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that David P. Southwell has been appointed to the HGS Board of Directors. He will also serve as...0700000007005000090000000901500004000000040020000400200604002001040160000401600813000000130010001300100213010000130100050701400007014004070140127/24/2008 8:22:55 AM1800000018007000PR Newswire USPRN-0005-26893012HUMAN GENOME SCIENCES INCSEPRACOR INCDAVID P SOUTHWELLThomas WatkinsHGSISEPRNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1827443ccbn/T1827443norm... - Merrill Lynch - AnalystGood morning, everyone. Our next presenting company is Sepracor, and with us to talk about the company is Adrian Adams, Chief Executive Officer. Adrian's been at the company just about a year now, and in this short order, he's had quite a few accomplishments. He's launched a new drug, Brovana, he's significantly restructured the sales force, he's brought in three long-life-cycle drugs, and just last week, he put together a fairly lengthy duration settlement with a generic challenger, Breath. So to walk you through the Sepracor story and then answer your questions, I'd like to introduce Adrian Adams, Chief Executive Officer.... 5/6/2008 7:06:00 PMSepracor54.0000FinalSepracor at Deutsche Bank Securities Inc. Health Care Conference TranscriptSEPR10:50am ETTranscriptT1827443Credit & Investment ResearchThomson StreetEventsCANADA - Sepracor Inc agreed to acquire all the outstanding stock of Oryx Pharmaceuticals Inc, a manufacturer of pharmaceuticals, for ##.### mil Canadian dollars ($## mil US). The consideration was to consist of C$##.### mil ($## mil) and up to C$##.## mil ($## mil) in profit-related payments. The transaction was subject to customary closing conditions.5/2/2008 11:59:26 AM81731568762M81731568762MSepracor IncOryx Pharmaceuticals IncSepracor IncOryx Pharmaceuticals Inchttp://www.alacrastore.com/storecontent/Thomson_M%26A/Sepracor_Inc_acquires_Oryx_Pharmaceuticals_Inc-1974158040sdc/19741580401974158040Copyright © 2008, Thomson Financial, All Rights ReservedNasdaqDrugsUnited StatesPharmaceutical preparations2834MAMassachusettsPublicSEPR2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances8742:Management consulting services2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances8742:Management consulting servicesDrugsCanadaPharmaceutical preparations2834FFForeignPrivate155354002Mnfr pharmaceuticalsMnfr pharmCashEarnoutStock781592001May 2 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.0000017.0000018.0000019.0000020.0000021.0000022.0000023.0000024.0000025.0000026.0000027.0000028.00000Sepracor Inc, located inMarlborough, Massachusetts,develops, manufacrures andcommercialize differentiatedproducts that address largeand growing markets, unmetmedical needs, and areprescribed principally byprimary care physicians. Themajor products of the Groupinclude XOPENEX(R)(levalbuterol HCl) InhalationSolution, for the treatment ofbronchospasm. XOPENEX HFAO(levalbuterol tartrate)Inhalation Aerosol, ahydrofluoroalkane,metered-dose inhaler for thetreatment of bronchospasm.LUNESTAO (eszopiclone), forthe treatment of insomnia. TheGroup's products are marketedto primary care physicians,allergists, pulmonologists,pediatricians, hospitals,psychiatrists and sleepspecialists. The company wasfounded in 1984.Sepracor Inc, located in Marlborough, Massachusetts,develops, manufacrures and commercialize differentiatedproducts that address large and growing markets, unmetmedical needs, and are prescribed principally by primarycare physicians. The major products of the Group includeXOPENEX(R) (levalbuterol HCl) Inhalation Solution, for thetreatment of bronchospasm. XOPENEX HFAO (levalbuteroltartrate) Inhalation Aerosol, a hydrofluoroalkane,metered-dose inhaler for the treatment of bronchospasm.LUNESTAO (eszopiclone), for the treatment of insomnia. TheGroup's products are marketed to primary care physicians,allergists, pulmonologists, pediatricians, hospitals,psychiatrists and sleep specialists. The company was foundedin 1984.Sepracor Inc, located in Marlborough, Massachusetts, develops, manufacrures and commercialize differentiated products that address large and growing markets, unmet medical needs, and are prescribed principally by primary care physicians. The major products of the Group include XOPENEX(R) (levalbuterol HCl) Inhalation Solution, for the treatment of bronchospasm. XOPENEX HFAO (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane, metered-dose inhaler for the treatment of bronchospasm. LUNESTAO (eszopiclone), for the treatment of insomnia. The Group's products are marketed to primary care physicians, allergists, pulmonologists, pediatricians, hospitals, psychiatrists and sleep specialists. The company was founded in 1984.1.000002.000003.000004.000005.000006.000007.00000Oryx Pharmaceuticals Inc,located in Mississauga,Ontario, manufacturesprescription pharmaceuticalsfocused in the therapeuticareas of CNS, cardiovasculardisease and oncologyOryx Pharmaceuticals Inc, located in Mississauga, Ontario,manufactures prescription pharmaceuticals focused in thetherapeutic areas of CNS, cardiovascular disease andoncologyOryx Pharmaceuticals Inc, located in Mississauga, Ontario, manufactures prescription pharmaceuticals focused in the therapeutic areas of CNS, cardiovascular disease and oncology0.000000.000000.000000.00000YCanadian Dollar01 May 08Thu, 01 May 2008 00:00:00 ESTDate Announced: 05/01/2008Date Effective:MergerFriendly0.000000.000000.000000.000000.000000.00000Price/Share0.0000070.455 Canadian Dollar70.455000.0000070.455 Canadian Dollar70.455000.000000.000000.000000.0000070.4550070.455 Canadian Dollar0.99400N35.238000.000000.000000.000000.000000.0000070.0000070.000000.000000.000000.000000.000000.000000.000000.00000100.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.00000CANADA - Sepracor Inc agreedto acquire all the outstandingstock of Oryx PharmaceuticalsInc, a manufacturer ofpharmaceuticals, for 70.455mil Canadian dollars ($70 milUS). The consideration was toconsist of C$50.325 mil ($50mil) and up to C$20.13 mil($20 mil) in profit-relatedpayments. The transaction wassubject to customary closingconditions.CANADA - Sepracor Inc agreed to acquire all the outstanding stock of Oryx Pharmaceuticals Inc, a manufacturer of pharmaceuticals, for 70.455 mil Canadian dollars ($70 mil US). The consideration was to consist of C$50.325 mil ($50 mil) and up to C$20.13 mil ($20 mil) in profit-related payments. The transaction was subject to customary closing conditions.CANADA - Sepracor Inc agreed to acquire all the outstanding stock of Oryx PharmaceuticalsInc, a manufacturer of pharmaceuticals, for 70.455 mil Canadian dollars ($70 mil US). Theconsideration was to consist of C$50.325 mil ($50 mil) and up to C$20.13 mil ($20 mil) inprofit-related payments. The transaction was subject to customary closing conditions.CANADA - Sepracor Inc agreed to acquire all the outstanding stock of Oryx Pharmaceuticals Inc, a manufacturer of pharmaceuticals, for 70.455 mil Canadian dollars ($70 mil US). The consideration was toconsist of C$50.325 mil ($50 mil) and up to C$20.13 mil ($20 mil) in profit-related payments. The transaction was subject to customary closing conditions.CANADA - Sepracor Inc agreed to acquire all the outstanding stock of Oryx Pharmaceuticals Inc, a manufacturer of pharmaceuticals, for70.455 mil Canadian dollars ($70 mil US). The consideration was to consist of C$50.325 mil ($50 mil) and up to C$20.13 mil ($20 mil) inprofit-related payments. The transaction was subject to customary closing conditions.Pending0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Pending-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances155354002NasdaqUnited States2834MassachusettsPublicSEPR2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances781592001Canada2834ForeignPrivate70.0000070.4550070.0000035.23800Deal InformationTF Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/ccbn/T1838505ccbn/T1838505norm...Welcome to Sepracor's first quarter #### earnings conference call. Hosting the call today from Sepracor is Mr. Adrian Adams, President and Chief Executive Officer. At this time all participants have been placed in a listen-only mode, and the floor will be open for your questions following the presentation. (OPERATOR INSTRUCTIONS). It is now my pleasure to turn the floor over to your host, Mr. Adrian Adams. Sir you may begin. ... 5/1/2008 11:06:00 AMSepracor54.0000FinalQ1 2008 Sepracor Earnings Conference Call TranscriptSEPR8:30am ETTranscriptT1838505Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1779842ccbn/T1779842norm... - Cowen and Company - AnalystGreat. Well, we're very pleased to have with us today Sepracor, and we've got a senior management team led by CEO Adrian Adams; the VP of R&D, Mark Corrigan; and Senior VP of Investor Relations, Jonae Barnes. And I think Adrian has done a terrific job here turning the focus at Sepracor back to the pipeline, and there are a lot of events coming up over this year and next that I think will bring enhanced visibility. And with that, turn it over to Adrian. ... 3/17/2008 6:05:00 PMSepracor54.0000FinalSepracor at Cowen & Company Annual Health Care Conference TranscriptSEPR2:30pm ETTranscriptT1779842Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1748504ccbn/T1748504norm...Welcome to Sepracor's fourth-quarter and full-year #### earnings conference call. Hosting the call today from Sepracor is Mr. Adrian Adams, President and Chief Executive Officer. At this time all participants have been placed in a listen-only mode and the floor will be open for your questions following the presentation. (OPERATOR INSTRUCTIONS) It is now my pleasure to turn the floor over to your host, Mr. Adrian Adams. Sir, you may begin. ... 2/29/2008 10:06:00 AMSepracor54.0000FinalQ4 2007 Sepracor Earnings Conference Call TranscriptSEPR8:30am ETTranscriptT1748504Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1672852ccbn/T1672852norm10/30/2007 10:05:00 AMSepracor54.0000FinalQ3 2007 Sepracor Earnings Conference Call TranscriptSEPR8:30am ET...Welcome to the Sepracor's third quarter #### earnings conference call. Hosting the call today from Sepracor is Mr. Adrian Adams, President and Chief Executive Officer. At this time, all participants have been placed in a listen-only mode and the floor will be opened for your questions following the presentation. (OPERATOR INSTRUCTIONS) ... TranscriptT1672852Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/srp/26133srp/26133norm... ##### Incorporated:DelawareWeb Site: www.sepracor.comSIC Classification: Pharmaceutical Preparations (####) Business Description: Sepracor Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease through the discovery, development and commercialization of innovative pharmaceutical compounds. The company is concentrating its product development efforts in two major therapeutic areas, respiratory and central nervous system disorders. Indices:Russell ####, Russell ####, S&P ### ... 26133817315104SEPR10/6/2006 12:23:00 PM26133Credit & Investment ResearchSharkRepellent.net